Browse
related articles
Pfizer eyes Mideast acquisitions
- Middle East: Monday, June 15 - 2009 at 11:03
Guy Lallemand, Pfizer's regional president for Africa & Middle East, has told Bloomberg that the region's respect for patents, openness toward clinical trials and rapid review of products has encouraged the US-based firm to consider making acquisitions in the more established markets such as Egypt, Saudi Arabia and the rest of the Gulf. 2009 Middle East sales are expected to be around $500 million and the company is forecasting between 8% and 10% annual growth, he said. Iraq, Iran and Syria are among markets where Pfizer is looking to expand its business, Lallemand added.
Related Content
Article Options
Disclaimer »
Articles in this section are primarily provided directly by the companies appearing or PR agencies which are solely responsible for the content. The companies concerned may use the above content on their respective web sites provided they link back to http://www.ameinfo.com
Any opinions, advice, statements, offers or other information expressed in this section of the AMEinfo.com Web site are those of the authors and do not necessarily reflect the views of AME Info FZ LLC / Emap Limited. AME Info FZ LLC / Emap Limited is not responsible or liable for the content, accuracy or reliability of any material, advice, opinion or statement in this section of the AMEinfo.com Web site.
For details about submitting your stories, please read the guide - all content published is subject to our terms and conditions
